Developer docs
API playgroundTry for free, no card

Search company profiles

ETAP-Lab

Full company profile

uuid000okgg

Namestring
ETAP-Lab
Legal namestring
SA ETAP
Websiteurl
etap-lab.com
Company typeenum
Private
Founded yearint
1991
Descriptiontext

ETAP-LAB is an independent French preclinical contract research organization (CRO) founded in 1991 as a spin-off of the Laboratory of Biology and Behavioral Physiology at UHP Nancy and headquartered in Vandœuvre-lès-Nancy. The company provides efficacy testing and non-GLP preclinical pharmacology services that span the drug-discovery continuum — from in vitro lead optimization through in vivo POC, PK/PD, and non-regulatory safety assessment — evaluating small molecules, antibodies, biotherapies, cell therapies, medical devices, and nutraceutical ingredients for pharmaceutical, biotechnology, medical device, nutraceutical, and academic sponsors. Since 2014, under CEO Nicolas Violle and a restructured management team, the firm has roughly sextupled headcount to 39 employees and tripled revenue (from €2M in 2019 to over €4M in 2023), combining organic growth with the October 2023 acquisition of cardiovascular specialist SYNCROSOME in Marseille.

The company operates through four specialized service brands — BRAINXPLORE (CNS/neurodegenerative), SKINAXIS (dermatology/wound healing), STROK@LLIANCE (neurovascular/stroke), and SYNCROSOME (cardiovascular) — each backed by proprietary technology platforms. Differentiated capabilities include a microfluidic brain-on-chip platform in SBS-formatted plates, know-how for reproducible production of human pathological oligomers (Aβ, α-synuclein, Tau, TDP-43), AI-enhanced high-content imaging (Revvity Operetta CLS), preclinical medical imaging (7T MRI, 3T MRI, hybrid MRI-PET, MPI) accessed through the CYCERON imaging platform, a whole-blood ROTEM hematology lab, and full behavioral assessment suites. ETAP-LAB holds ISO 9001 certification for its Nancy and Caen facilities and is authorized to handle Class 1 GM and immunodeficient rodent strains under EU Directive 2010/63/EU.

Revenue is generated through project-based B2B contracts priced per study, with a direct enterprise sales model featuring dedicated Study Directors and a 48-hour inquiry response time. Marketing is concentrated on scientific credibility channels — peer-reviewed publications, conference posters (e.g., BIO International 2026 in San Diego), LinkedIn, Gircor industry engagement, and quarterly newsletters — rather than mass-market campaigns. The company is privately held as SA ETAP with no disclosed institutional investors; growth has been financed organically plus a single disclosed acquisition, supplemented by France 2030 program selection (BIO-DIAMOND 2022, Bpifrance Accélérateur 2024) for non-dilutive capability and international expansion support.

Short descriptiontext

ETAP-LAB is an independent French preclinical CRO providing integrated in vitro and in vivo pharmacology services across neurology, dermatology, neurovascular/stroke, and cardiovascular therapeutics for pharma, biotech, medical device, nutraceutical, and academic sponsors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVandoeuvre-lès-nancy, France
HQ citystring
Vandoeuvre-lès-nancy
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical CRO, pharmacology services, drug efficacy testing, contract research, preclinical studies
Industry3 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAFAA
In Vivo Pharmacology (Efficacy/PD Models)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Preclinical Contract Research Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Preclinical CRO Services
TypeProfessional Services
Description

Contract research services providing efficacy testing and preclinical pharmacology to pharmaceutical, biotechnological, and nutraceutical industries. Services support drug discovery phases from in vitro lead optimization through non-GLP animal studies (POC, PK/PD, non-regulatory safety). Revenue generated through project-based contracts for study design, execution, and reporting.

etap-lab.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1BRAINXPLORE
Description

Neurology and CNS preclinical services brand offering integrated range of services for neurodegenerative diseases and behavioral pharmacology, from in vitro models to in vivo studies.

etap-lab.com
+3 more records
Core offering1 text field

ETAP-LAB is an independent preclinical Contract Research Organization (CRO) providing efficacy testing and preclinical pharmacology services to pharmaceutical, biotechnology, nutraceutical, and medical device industries. Services span drug discovery phases from in vitro lead optimization through non-GLP animal studies (proof-of-concept, PK/PD, non-regulatory safety), evaluating small molecules, antibodies, biotherapies, cell therapies, medical devices, and nutraceuticals. The offering is organized under four specialized service brands: BRAINXPLORE (neurology/CNS), SKINAXIS (dermatology), STROK@LLIANCE (neurovascular/stroke), and SYNCROSOME (cardiovascular).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Customer satisfaction rating of 9.3/10 (100% CSAT 2024)
+4 more records
Product overview1 text field

ETAP-LAB is an independent preclinical CRO providing comprehensive pharmacology services to pharmaceutical, biotechnology, and nutraceutical industries. The company operates under a unified umbrella brand architecture with four specialized service brands: BRAINXPLORE (neurology/CNS with focus on neurodegenerative diseases), SKINAXIS (dermatology and inflammatory skin conditions), STROK@LLIANCE (neurovascular and stroke research), and SYNCROSOME (cardiovascular and cardiopulmonary pathologies). Supporting these brands, ETAP-LAB offers integrated technology platforms including High Content Imaging, Brain-on-Chip, preclinical medical imaging, and comprehensive analytical services, enabling end-to-end preclinical research from in vitro cell systems through in vivo animal studies to PK/PD and safety assessments.

Product and service10 records
1BRAINXPLORE
CategoryNeurology / CNS preclinical CRO services
Description

Service brand dedicated to CNS and neurodegenerative diseases, offering integrated in vitro and in vivo preclinical pharmacology services for conditions such as Alzheimer's and Parkinson's disease, including behavioral pharmacology assessments. Targeted at pharmaceutical and biotech clients developing CNS drug candidates.

2SKINAXIS
CategoryDermatology preclinical CRO services
Description

Service brand specializing in dermatology for preclinical evaluation of drug efficacy and medical devices. Offers models for inflammatory skin diseases, wound healing, skin grafting, and dermal toxicity testing, with over 20 years of expertise. Targeted at pharmaceutical, biotech, and medical device developers.

3STROK@LLIANCE
CategoryNeurovascular / stroke preclinical CRO services
Description

Service brand focused on neurovascular pathologies and stroke, offering translational models from in vitro screening on human blood to complex animal models with integrated comorbidities, combined with advanced imaging capabilities.

4SYNCROSOME
CategoryCardiovascular preclinical CRO services
Description

Service brand specializing in cardiovascular pharmacology with over 25 years of expertise, offering models for cardiovascular, cardiometabolic, cardiopulmonary, and thrombotic diseases. Targeted at pharmaceutical and biotech clients developing cardiovascular therapeutics.

5In Vitro Efficacy Studies
CategoryIn vitro preclinical services
Description

Cell culture-based efficacy studies including models of neurodegenerative diseases or stroke using primary neurons or human iPSCs, brain-on-chip models combined with high-content imaging, and hematology studies on whole human blood for thrombolytics and anticoagulants evaluation.

6In Vivo Efficacy Studies
CategoryIn vivo preclinical services
Description

Efficacy studies using gold-standard and innovative rodent and pig models reproducing key pathophysiological mechanisms of target human diseases, with translational readouts including medical imaging, behavior, and histology to support regulatory dossiers.

7PK/PD Services
CategoryPharmacokinetics / pharmacodynamics services
Description

Pharmacokinetics and pharmacodynamics studies compatible with all in vivo models, including neuro-PK studies evaluating compound bioavailability in the brain, supported by a network of trusted partners for analytical methods and assays.

8Non-Regulatory Safety Studies
CategoryNon-regulatory safety pharmacology services
Description

Specialist safety assessment for drugs in the neurovascular field, including hemorrhagic transformation risk, intracranial and peripheral hemorrhage risk, and pharmacological interactions with fibrinolytic or antithrombotic treatments; ETAP-LAB has supported INDs for numerous molecules via these studies.

9Analytical Services
CategoryAnalytical and biological readout services
Description

Biological analysis services including immunohistochemistry, immunofluorescence, histology, immunoassays (ELISA, ELLA Simple Plex), Western blotting, plus coordinated outsourced services for mass spectrometry, RNA-Seq, and flow cytometry.

10Scientific Consulting
CategoryScientific advisory services
Description

Scientific advisory services covering model selection, protocol design, technical and scientific responses to drug evaluation agencies, research promotion (publications, posters, presentations), and independent result evaluation through a network of scientific KOLs.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1PhIND Laboratory (INSERM/UniCaen)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Public-private partnership for stroke research. STROK@LLIANCE was created as a partnership with PhIND laboratory (UMR-1237, INSERM/UniCaen) led by Prof. Denis Vivien to industrialize innovative stroke models developed by academic research and make them accessible for routine CRO studies. Located next to CYCERON imaging center and BB@C institute in one of the world's most dynamic stroke research ecosystems.

etap-lab.com
2CYCERON Imaging Platform
Strategic tierCoreTypeTechnology or Integration
Description

Long-standing partnership with CYCERON imaging platform in Caen, located directly next to ETAP-LAB facilities. Provides privileged access to state-of-the-art medical imaging tools including 7T MRI, 3T MRI, hybrid MRI-PET, and MPI within an internationally recognized infrastructure.

etap-lab.com
3French Blood Establishment (EFS)
Strategic tierCoreTypeTechnology or Integration
Description

Agreement with EFS ensuring convenient local access to human blood samples for hemostasis and thrombolysis research applications in hematology laboratory.

etap-lab.com
4BB@C Institute
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Located next to BB@C institute as part of the dynamic stroke research ecosystem in Caen, France.

etap-lab.com
Strategic tierMinorTypeOthers
Description

ETAP-LAB is a member of Gircor and participates in industry discussions on preclinical evaluation challenges, transparency in animal research, and 3R principles application.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Integrated drug discovery CRO with growing preclinical capabilities in CNS and inflammatory diseases. Comparable mid-sized competitor with growing international footprint.

TypeDirect peer
Description

France-based preclinical CRO specializing in pharmacology and safety pharmacology services. Directly competes with ETAP-Lab in CNS and behavioral pharmacology with similar in vitro/in vivo capabilities.

TypeBroad incumbent
Description

Global CRO/CDMO with preclinical pharmacology and safety assessment services across multiple therapeutic areas including CNS and cardiovascular. Operates at significantly larger scale than ETAP-Lab.

TypeBroad incumbent
Description

Global bioanalytical and contract research services provider with extensive preclinical testing capabilities. Overlapping offerings in pharmacology and analytical services for pharma/biotech clients.

TypeBroad incumbent
Description

Global CRO offering preclinical research services including CNS, cardiovascular, and dermatology models. Much larger scale across all therapeutic areas and offers integrated IND-enabling studies that ETAP-Lab does not.

TypeBroad incumbent
Description

European CRO/CDMO with substantial preclinical neuroscience, stroke, and inflammatory disease operations. Competes across CNS, dermatology, and cardiovascular therapeutic areas at much larger scale.

TypeBroad incumbent
Description

Global CDMO/CRO offering preclinical research and development services across multiple therapeutic areas. Broader incumbent competing for pharma/biotech preclinical outsourcing budgets.

TypeBroad incumbent
Description

Global CRO providing preclinical drug discovery and development services including in vivo pharmacology across multiple therapeutic areas. Larger-scale alternative for pharma/biotech sponsors.

TypeDirect peer
Description

European preclinical CRO offering in vivo efficacy and safety studies in neurology, cardiovascular, and metabolic disease models. Comparable mid-sized competitor with overlapping target customers.

TypeDirect peer
Description

Preclinical CRO specialized in CNS, pain, and neurodegenerative disease research with electrophysiology and behavioral readouts. Closely overlaps with ETAP-Lab's BRAINXPLORE offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ETAP-Lab

Preclinical Contract Research Servicesetap-lab.com

ETAP-LAB is an independent French preclinical CRO providing integrated in vitro and in vivo pharmacology services across neurology, dermatology, neurovascular/stroke, and cardiovascular therapeutics for pharma, biotech, medical device, nutraceutical, and academic sponsors.

What ETAP-Lab does

ETAP-LAB is an independent French preclinical contract research organization (CRO) founded in 1991 as a spin-off of the Laboratory of Biology and Behavioral Physiology at UHP Nancy and headquartered in Vandœuvre-lès-Nancy. The company provides efficacy testing and non-GLP preclinical pharmacology services that span the drug-discovery continuum — from in vitro lead optimization through in vivo POC, PK/PD, and non-regulatory safety assessment — evaluating small molecules, antibodies, biotherapies, cell therapies, medical devices, and nutraceutical ingredients for pharmaceutical, biotechnology, medical device, nutraceutical, and academic sponsors. Since 2014, under CEO Nicolas Violle and a restructured management team, the firm has roughly sextupled headcount to 39 employees and tripled revenue (from €2M in 2019 to over €4M in 2023), combining organic growth with the October 2023 acquisition of cardiovascular specialist SYNCROSOME in Marseille.

The company operates through four specialized service brands — BRAINXPLORE (CNS/neurodegenerative), SKINAXIS (dermatology/wound healing), STROK@LLIANCE (neurovascular/stroke), and SYNCROSOME (cardiovascular) — each backed by proprietary technology platforms. Differentiated capabilities include a microfluidic brain-on-chip platform in SBS-formatted plates, know-how for reproducible production of human pathological oligomers (Aβ, α-synuclein, Tau, TDP-43), AI-enhanced high-content imaging (Revvity Operetta CLS), preclinical medical imaging (7T MRI, 3T MRI, hybrid MRI-PET, MPI) accessed through the CYCERON imaging platform, a whole-blood ROTEM hematology lab, and full behavioral assessment suites. ETAP-LAB holds ISO 9001 certification for its Nancy and Caen facilities and is authorized to handle Class 1 GM and immunodeficient rodent strains under EU Directive 2010/63/EU.

Revenue is generated through project-based B2B contracts priced per study, with a direct enterprise sales model featuring dedicated Study Directors and a 48-hour inquiry response time. Marketing is concentrated on scientific credibility channels — peer-reviewed publications, conference posters (e.g., BIO International 2026 in San Diego), LinkedIn, Gircor industry engagement, and quarterly newsletters — rather than mass-market campaigns. The company is privately held as SA ETAP with no disclosed institutional investors; growth has been financed organically plus a single disclosed acquisition, supplemented by France 2030 program selection (BIO-DIAMOND 2022, Bpifrance Accélérateur 2024) for non-dilutive capability and international expansion support.

ETAP-Lab firmographics

Firmographics
Name
ETAP-Lab
Legal name
SA ETAP
Website
https://etap-lab.com
Company type
Private
Founded year
1991
Operating status
Operating
Headcount range
11–50 employees
Short description
ETAP-LAB is an independent French preclinical CRO providing integrated in vitro and in vivo pharmacology services across neurology, dermatology, neurovascular/stroke, and cardiovascular therapeutics for pharma, biotech, medical device, nutraceutical, and academic sponsors.
Ownership category
akta.pro rank

ETAP-Lab industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAFAA
In Vivo Pharmacology (Efficacy/PD Models)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)

Keywords

  • Preclinical CRO
  • Pharmacology services
  • Drug efficacy testing
  • Contract research
  • Preclinical studies

Where ETAP-Lab is headquartered

Location

Headquarters

HQ city
Vandoeuvre-lès-nancy
HQ country
France
HQ region
Europe

Offices3 records

Markets served

ETAP-Lab business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Preclinical CRO Services: Contract research services providing efficacy testing and preclinical pharmacology to pharmaceutical, biotechnological, and nutraceutical industries. Services support drug discovery phases from in vitro lead optimization through non-GLP animal studies (POC, PK/PD, non-regulatory safety). Revenue generated through project-based contracts for study design, execution, and reporting.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

ETAP-Lab product offering

Product offering

Core offering

ETAP-LAB is an independent preclinical Contract Research Organization (CRO) providing efficacy testing and preclinical pharmacology services to pharmaceutical, biotechnology, nutraceutical, and medical device industries. Services span drug discovery phases from in vitro lead optimization through non-GLP animal studies (proof-of-concept, PK/PD, non-regulatory safety), evaluating small molecules, antibodies, biotherapies, cell therapies, medical devices, and nutraceuticals. The offering is organized under four specialized service brands: BRAINXPLORE (neurology/CNS), SKINAXIS (dermatology), STROK@LLIANCE (neurovascular/stroke), and SYNCROSOME (cardiovascular).

Product overview

ETAP-LAB is an independent preclinical CRO providing comprehensive pharmacology services to pharmaceutical, biotechnology, and nutraceutical industries. The company operates under a unified umbrella brand architecture with four specialized service brands: BRAINXPLORE (neurology/CNS with focus on neurodegenerative diseases), SKINAXIS (dermatology and inflammatory skin conditions), STROK@LLIANCE (neurovascular and stroke research), and SYNCROSOME (cardiovascular and cardiopulmonary pathologies). Supporting these brands, ETAP-LAB offers integrated technology platforms including High Content Imaging, Brain-on-Chip, preclinical medical imaging, and comprehensive analytical services, enabling end-to-end preclinical research from in vitro cell systems through in vivo animal studies to PK/PD and safety assessments.

Differentiator

Problem solved

Functional benefit

Brands

  • BRAINXPLORE: Neurology and CNS preclinical services brand offering integrated range of services for neurodegenerative diseases and behavioral pharmacology, from in vitro models to in vivo studies.
  • SKINAXIS
  • STROK@LLIANCE
  • SYNCROSOME

Products and services

  • BRAINXPLORE Service brand dedicated to CNS and neurodegenerative diseases, offering integrated in vitro and in vivo preclinical pharmacology services for conditions such as Alzheimer's and Parkinson's disease, including behavioral pharmacology assessments. Targeted at pharmaceutical and biotech clients developing CNS drug candidates.
  • SKINAXIS Service brand specializing in dermatology for preclinical evaluation of drug efficacy and medical devices. Offers models for inflammatory skin diseases, wound healing, skin grafting, and dermal toxicity testing, with over 20 years of expertise. Targeted at pharmaceutical, biotech, and medical device developers.
  • STROK@LLIANCE Service brand focused on neurovascular pathologies and stroke, offering translational models from in vitro screening on human blood to complex animal models with integrated comorbidities, combined with advanced imaging capabilities.
  • SYNCROSOME Service brand specializing in cardiovascular pharmacology with over 25 years of expertise, offering models for cardiovascular, cardiometabolic, cardiopulmonary, and thrombotic diseases. Targeted at pharmaceutical and biotech clients developing cardiovascular therapeutics.
  • In Vitro Efficacy Studies Cell culture-based efficacy studies including models of neurodegenerative diseases or stroke using primary neurons or human iPSCs, brain-on-chip models combined with high-content imaging, and hematology studies on whole human blood for thrombolytics and anticoagulants evaluation.
  • In Vivo Efficacy Studies Efficacy studies using gold-standard and innovative rodent and pig models reproducing key pathophysiological mechanisms of target human diseases, with translational readouts including medical imaging, behavior, and histology to support regulatory dossiers.
  • PK/PD Services Pharmacokinetics and pharmacodynamics studies compatible with all in vivo models, including neuro-PK studies evaluating compound bioavailability in the brain, supported by a network of trusted partners for analytical methods and assays.
  • Non-Regulatory Safety Studies Specialist safety assessment for drugs in the neurovascular field, including hemorrhagic transformation risk, intracranial and peripheral hemorrhage risk, and pharmacological interactions with fibrinolytic or antithrombotic treatments; ETAP-LAB has supported INDs for numerous molecules via these studies.
  • Analytical Services Biological analysis services including immunohistochemistry, immunofluorescence, histology, immunoassays (ELISA, ELLA Simple Plex), Western blotting, plus coordinated outsourced services for mass spectrometry, RNA-Seq, and flow cytometry.
  • Scientific Consulting Scientific advisory services covering model selection, protocol design, technical and scientific responses to drug evaluation agencies, research promotion (publications, posters, presentations), and independent result evaluation through a network of scientific KOLs.

Quantifiable outcome

  • Customer satisfaction rating of 9.3/10 (100% CSAT 2024)
  • +4 more outcomes

Companies that use ETAP-Lab

Customer profile

Named customers14 records

Segments4 records

Ideal customer profiles4 records

ETAP-Lab technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

ETAP-Lab partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • PhIND Laboratory (INSERM/UniCaen)coreStrategic or Co-development Partner · 1 January 2017Public-private partnership for stroke research. STROK@LLIANCE was created as a partnership with PhIND laboratory (UMR-1237, INSERM/UniCaen) led by Prof. Denis Vivien to industrialize innovative stroke models developed by academic research and make them accessible for routine CRO studies. Located next to CYCERON imaging center and BB@C institute in one of the world's most dynamic stroke research ecosystems.
  • CYCERON Imaging PlatformcoreTechnology or IntegrationLong-standing partnership with CYCERON imaging platform in Caen, located directly next to ETAP-LAB facilities. Provides privileged access to state-of-the-art medical imaging tools including 7T MRI, 3T MRI, hybrid MRI-PET, and MPI within an internationally recognized infrastructure.
  • French Blood Establishment (EFS)coreTechnology or IntegrationAgreement with EFS ensuring convenient local access to human blood samples for hemostasis and thrombolysis research applications in hematology laboratory.
  • BB@C InstitutecoreStrategic or Co-development PartnerLocated next to BB@C institute as part of the dynamic stroke research ecosystem in Caen, France.
  • GircorminorOthersETAP-LAB is a member of Gircor and participates in industry discussions on preclinical evaluation challenges, transparency in animal research, and 3R principles application.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

ETAP-Lab competitors and assessment

Company assessment

Emerging players

  • Sygnature Discovery: Integrated drug discovery CRO with growing preclinical capabilities in CNS and inflammatory diseases. Comparable mid-sized competitor with growing international footprint.

Direct peers

  • Porsolt: France-based preclinical CRO specializing in pharmacology and safety pharmacology services. Directly competes with ETAP-Lab in CNS and behavioral pharmacology with similar in vitro/in vivo capabilities.
  • InnoSer: European preclinical CRO offering in vivo efficacy and safety studies in neurology, cardiovascular, and metabolic disease models. Comparable mid-sized competitor with overlapping target customers.
  • Neuroservices-Alliance: Preclinical CRO specialized in CNS, pain, and neurodegenerative disease research with electrophysiology and behavioral readouts. Closely overlaps with ETAP-Lab's BRAINXPLORE offering.

Broad incumbents

  • Wuxi AppTec: Global CRO/CDMO with preclinical pharmacology and safety assessment services across multiple therapeutic areas including CNS and cardiovascular. Operates at significantly larger scale than ETAP-Lab.
  • Eurofins Scientific: Global bioanalytical and contract research services provider with extensive preclinical testing capabilities. Overlapping offerings in pharmacology and analytical services for pharma/biotech clients.
  • Charles River Laboratories: Global CRO offering preclinical research services including CNS, cardiovascular, and dermatology models. Much larger scale across all therapeutic areas and offers integrated IND-enabling studies that ETAP-Lab does not.
  • Evotec: European CRO/CDMO with substantial preclinical neuroscience, stroke, and inflammatory disease operations. Competes across CNS, dermatology, and cardiovascular therapeutic areas at much larger scale.
  • Curia: Global CDMO/CRO offering preclinical research and development services across multiple therapeutic areas. Broader incumbent competing for pharma/biotech preclinical outsourcing budgets.
  • Pharmaron: Global CRO providing preclinical drug discovery and development services including in vivo pharmacology across multiple therapeutic areas. Larger-scale alternative for pharma/biotech sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

ETAP-Lab social profiles

Digital presence

ETAP-Lab compliance and trust

Trust signal

Compliance2 records

ETAP-Lab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ETAP-Lab leadership team

Management profile

Number of profiles

Profiles3 records

ETAP-Lab subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

ETAP-Lab funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ETAP-Lab M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ETAP-Lab

What does ETAP-Lab do?

ETAP-LAB is an independent preclinical Contract Research Organization (CRO) providing efficacy testing and preclinical pharmacology services to pharmaceutical, biotechnology, nutraceutical, and medical device industries. Services span drug discovery phases from in vitro lead optimization through non-GLP animal studies (proof-of-concept, PK/PD, non-regulatory safety), evaluating small molecules, antibodies, biotherapies, cell therapies, medical devices, and nutraceuticals. The offering is organized under four specialized service brands: BRAINXPLORE (neurology/CNS), SKINAXIS (dermatology), STROK@LLIANCE (neurovascular/stroke), and SYNCROSOME (cardiovascular).

Is ETAP-Lab a public or private company?

ETAP-Lab is a private company. It is classified as management employee owned and is currently operating.

When was ETAP-Lab founded?

ETAP-Lab was founded in 1991. It employs 11 to 50 people.

Where is ETAP-Lab based?

ETAP-Lab is headquartered in Vandoeuvre-lès-nancy, France, in the Europe region.

How does ETAP-Lab make money?

One revenue line is on record: preclinical CRO Services.

Who are ETAP-Lab's main competitors?

Sygnature Discovery is listed as an emerging player. Direct peers are Porsolt, InnoSer and Neuroservices-Alliance. Broad incumbents are Wuxi AppTec, Eurofins Scientific, Charles River Laboratories, Evotec, Curia and Pharmaron.

Does ETAP-Lab have an API?

No public API is recorded for ETAP-Lab.

What industry is ETAP-Lab in?

ETAP-Lab's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAFAA, In Vivo Pharmacology (Efficacy/PD Models). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals